VIICTR Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res. 2004 May 15; 64(10):3645-52.
View in:
PubMed
subject areas
Antineoplastic Combined Chemotherapy Protocols
Apoptosis
Benzoquinones
Cysteine Endopeptidases
DNA, Neoplasm
DNA-Binding Proteins
Drug Synergism
Enzyme Inhibitors
fms-Like Tyrosine Kinase 3
G1 Phase
HSP90 Heat-Shock Proteins
Humans
Lactams, Macrocyclic
Leukemia, Myeloid, Acute
Milk Proteins
Mitogen-Activated Protein Kinase 1
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinases
Multienzyme Complexes
Proteasome Endopeptidase Complex
Proto-Oncogene Proteins
Proto-Oncogene Proteins c-akt
Receptor Protein-Tyrosine Kinases
Rifabutin
Signal Transduction
STAT5 Transcription Factor
Staurosporine
Trans-Activators
Ubiquitin
authors with profiles
WARREN C FISKUS
KAPIL BHALLA